aod9604 fda status approval From BPC-157 to TB-500 to
Description
Ng, M., et al
The paper is Awosemo et al
This selectivity also explains why AOD 9604 does not cause the jitteriness, elevated heart rate, or anxiety that many other fat-loss compounds produce
These fatty acids must be oxidized (burned) to achieve net fat loss
High-dose supplementation, particularly hydroxocobalamin injections, has been associated with acne-like eruptions and rosacea flare-ups in susceptible individuals
